MD PhD | Cancer Gene&Cell Therapy @NaldiniLab, Milan | Visiting Scholar, @penn CCI | Medical Oncology fellow @MyUniSR, Milan | Alumnus @ScuolaSantAnna, Pisa
๐งต1/
๐จ Just out in Science Translational Medicine @ScienceTM our latest work @NaldiniLab:
We show how tumor-targeted cytokines can rescue CAR-T function and recruit endogenous T cells to fight glioblastoma, the toughest brain cancer.
๐https://t.co/dRuvDW6ISN
๐ Here's a thread:
Tumor-targeted cytokine delivery by engineered myeloid cells unlocks CAR T cell efficacy and endogenous T cell responses in glioblastoma @MolTherapy
on
https://t.co/uyT4tdHews @ScienceTM@NaldiniLab
Tumor-targeted cytokine delivery by engineered myeloid cells unlocks CAR T cell efficacy and endogenous T cell responses in glioblastoma https://t.co/YMT2CTC7kH #genetherapy#celltherapy
Our commentary is out in @MolTherapy!
How targeted cytokines help CAR T cells fight GBM by rewiring the TME & boosting immunity.
Details ๐ https://t.co/7csgjuuZDs
@NaldiniLab#Immunotherapy#CART#GBM
๐จ Paper Alert ๐จ
Truly honored for being part of this super project led by the fantastic @f_rossari out in @ScienceTM ! We showed how reprogramming the #TME via #HSC#engineering may restore #CART cell function also in #GBM !
Kudos to the super team who made this happen ๐
Out in @ScienceTM! The Naldini lab delivers another masterclass of stem/immune cell gene engineering to deliver cytokines in the TME and boost CAR-T cell activity in glioblastoma.
Kudos to @f_rossari@giorgiaalvisi and Nadia Coltella for this important study๐ฅ
Tumor-targeted cytokine delivery by TAMs establishes a private cross-talk that rescues CAR T cell function and engages host T cells to treat GBM
https://t.co/uyT4tdHMm0
@NaldiniLab@ScienceTM
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice | Science Translational Medicine https://t.co/7KqRGs4OCp
Excited to share our new study published inย JNCI! ๐งฌ
In >500 real-world BTC pts treated with cisplatin, gemcitabine & durvalumab, we found:โจโ๏ธ SMAD4 mut = better outcomesโจโ TP53 & TERT mut = worse survivalโจ๐ฌ A new clinico-molecular score for patients
https://t.co/RS2BSYVEl7
๐งต1/
๐จ Just out in Science Translational Medicine @ScienceTM our latest work @NaldiniLab:
We show how tumor-targeted cytokines can rescue CAR-T function and recruit endogenous T cells to fight glioblastoma, the toughest brain cancer.
๐https://t.co/dRuvDW6ISN
๐ Here's a thread: